The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: Is M1 agonism a pre-requisite for mimicking clozapine's actions?

Psychopharmacology

Volumn 178, Issue 4, 2005, Pages 451-460

  Davies, Marilyn A ^a   Compton Toth, Beth Ann ^a   Hufeisen, Sandra J ^a   Meltzer, Herbert Y ^b   Roth, Bryan L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic; Clozapine; Muscarinic; N desmethylclozapine

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; AMANTADINE; AMITRIPTYLINE; AMOXAPINE; AMPEROZIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BENZATROPINE; CARBACHOL; CLOZAPINE; CYPROHEPTADINE; DESIPRAMINE; FLUPERLAPINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; IMIPRAMINE; IPSAPIRONE; JL 13; KETANSERIN; LOXAPINE; MELPERONE; MEPYRAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M5 RECEPTOR; NORCLOZAPINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CLOZAPINE; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; PSYCHOPHARMACOLOGY; PYRIDINES; RECEPTORS, MUSCARINIC; THIADIAZOLES;

EID: 16844363204     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2017-1     Document Type: Article

References (69)

1. 2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16:517-525
2. 1a receptor. Cell Signal 11:743-751
3. Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576-580
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
5. Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P, Fink-Jensen A (1998) Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo [3.2.1]octane. Eur J Pharmacol 356:109-119
6. Bymaster FP, Felder C, Ahmed S, McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Target CNS Neurol Disord 1:163-181
7. Chavkin C, Sud S, Jin W, Steward J, Zjawiony JK, Siebert D, Toth BA, Hufeisen SJ, Roth BL (2004) Salvinorin A, an active component of the hallucinogenic sage salvia divinorum, is a highly efficacious kappa opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 368:1197-2003
8. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001) Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158:918-925
9. de Paulis T (2001) M-100907 (Aventis). Curr Opin Invest Drugs 2:123-132
10. 1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7:1083-1091
11. Dean B, Bymaster FP, Scarr E (2003) Muscarinic receptors in schizophrenia. Curr Mol Med 3:419-426
12. Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994) BMY14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40
13. Harrison PJ, Owen MJ (2003) Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417-419
14. Hodder P, Mull R, Cassaday J, Berry K, Strulovici B (2004) Miniaturization of intracellular calcium assays to 1536-well plate format using a fluorometric imaging plate reader. J Biomol Screen 9:417-426
15. 2 antagonistic properties. J Pharmacol Exp Ther 244:685-693
16. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C (1993) Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology 112:890-894
17. Kane J, Honigfield G, Singer J, Meltzer HY, Group at CCS (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
18. 1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121:328-329
19. Kassack MU, Hofgen B, Lehmann J, Eckstein J, Quillan JM, Sadee W (2002) Functional screening of G protein coupled receptors by measuring intracellular calcium with a fluorescence microplate reader. J Biomol Screen 7:233-246
20. Kenakin T (1997) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464
21. 6 serotonin receptor. J Neurochem 66:47-56
22. 4 Dopamine Antagonist Group. Arch Gen Psychiatry 54:567
23. Kroeze WK, Sheffler DJ, Roth BL (2003) G-protein-coupled receptors at a glance. J Cell Sci 116:4867-4869
24. 1C receptor antagonists. Eur J Pharmacol 245:179-182
25. 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm 105:719-734
26. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002) Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190
27. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-1589
28. Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Chang CY, Chen H, Tsai SJ (2003) Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 48:72-76
29. Meltzer HY, McGurk SR ( 1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
30. Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
31. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 60:82-91
32. Meltzer H, Arvantis L, Bauer D, Rein W, Group MS (2004) A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (in press)
33. Miller RJ, Hiley CR (1974) Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature (London) 248:546-547
34. Muller MJ, Grunder G, Wetzel H, Muller-Siecheneder F, Marx-Dannigkeit P, Benkert O (1999) Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res 89:275-280
35. Newcomer JW, Faustman WO, Zipursky RB, Csernansky JG (1992) Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial. Arch Gen Psychiatry 49:751-752
36. 35S]GTPgammaS binding study. Eur J Pharmacol 355:245-256
37. Olianas MC, Maullu C, Onali P (1999) Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20:263-270
38. Pfeiffer CC, Jenney EH (1957) The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann N Y Acad Sci 66:753-764
39. Potkin SG, Shipley J, Bera R, Carreon D, Fallon J, Alva G, Keator D (2001) Clinical and PET Effects of M100907, a selective 5HT-2A receptor antagonist. Schizophr Res 49:242
40. 3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia. Int Clin Psychopharmacol 14:357-360
41. Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR (2003a) Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28:1531-1537
42. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS, Egan MF, Coppola R, Weinberger DR (2003b) In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160:118-127
43. Rasmussen T, Fink-Jensen A, Sauerberg P, Swedberg MD, Thomsen C, Sheardown MJ, Jeppesen L, Calligaro DO, DeLapp NW, Whitesitt C, Ward JS, Shannon HE, Bymaster FP (2001) The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophr Res 49:193-201
44. Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83-89
45. Remington G, Kapur S (2001) SB-277011 GlaxoSmithKline. Curr Opin Invest Drugs 2:946-949
46. 1C receptors. J Pharmacol Exp Ther 260:1361-1365
47. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
48. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995) D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368
49. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939
50. Roth BL, Sheffler DJ, Potkin S (2003) Atypical antipsychotic drugs: unitary or multiple mechanisms for "atypicality". Clin Neurosci Res 3:108-117
51. Roth BL, Kroeze WK, Sheffler DJ (2004) Magic bullets vs magic shotguns: why selectively non-selective drugs are better for treating schizophrenia and depression. Nat Rev Drug Discov 3:359-364
52. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138-145
53. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
54. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA III et al. (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
55. Seibyl JP, Krystal JH, Pricer LH, Woods SW, Heninger GR, Charney DS (1989) 5-HT function in the biochemical and behavioral effects of MCPP in healthy subjects and schizophrenics. Soc Neurosci Abstr 15:1236
56. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229
57. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249-259
58. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411
59. Snyder S, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 31:58-61
60. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679
61. Tandon R (1999) Cholinergic aspects of schizophrenia. Br J Psychiatry Suppl 37:7-11
62. Tandon R, Greden JF (1987) Trihexyphenidyl treatment of negative schizophrenic symptoms. Acta Psychiatr Scand 76:732
63. Tandon R, Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753
64. Tuunainen A, Wahlbeck K, Gilbody S (2002) Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 56:1-10
65. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
66. 2 receptors. Br J Pharmacol 125:1413-1420
67. Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O (1995) Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119:231-238
68. 4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321:349-354
69. 4 receptor agonist. Eur J Pharmacol 269:R1-R2